



## Financial Tear Sheet

### Stock Performance

HAE (Common Stock)	
Exchange	NYSE (US Dollar)
Price	\$41.60
Change (%)	▲ 0.02 (0.05%)
Volume	72,048
52 Week Low	\$32.76
Market Cap	\$2,188,686,734
Rolling EPS	0.07
PE Ratio	594.357
Shares Outstanding	52,606,339
Data as of 08/21/17 1:20 p.m. ET	




### Recent Headlines & Events

- Aug. 07, 2017 - 6:00 a.m.  
[Haemonetics 1st Quarter Fiscal 2018 Earnings Release Available on Investor Relations Website](#)
- Jul. 28, 2017 - 8:31 a.m.  
[Haemonetics Announces FDA Clearance of New Plasmapheresis System Branded NexSys PCS™](#)
- Jul. 18, 2017 - 8:00 a.m.  
[Haemonetics Sets Date for Publishing 1st Quarter Fiscal 2018 Results: August 7, 2017](#)

There are currently no events scheduled.

### Analyst Estimates / Ratings

Mean Recommendation: 2.6



EPS Trend		Current	30 Days Ago	90 Days Ago
QTR	Sep 17	0.41	0.41	0.41
QTR	Dec 17	0.45	0.46	0.45
QTR	Mar 18	0.42	0.42	0.43
QTR	Jun 18	0.40	0.39	0.38
FY	Mar 18	1.61	1.60	1.60
FY	Mar 19	1.83	1.80	1.80

## IR Contact

For information or questions relating to share certificates such as address change requests, lost share claims, and more, please contact Haemonetics' transfer agent:

## Transfer Agent

Registrar & Transfer Company  
10 Commerce Drive  
Cranford, NJ 07016 USE  
Tel. 800-368-5948  
E-mail [info@rtco.com](mailto:info@rtco.com)

## Other investment-related questions:

[Contact us via e-mail](#)

Contact us via phone:  
US (800) 225-5242 extension 9402  
International (781) 356-9402

Contact us in writing:  
Haemonetics Corporation  
Attn: Investor Relations  
400 Wood Road  
Braintree, MA 02184

## Board of Directors

Richard Meelia	Chairman
Chris Simon	Director & CEO
Cathy Burzik	Director
Susan Bartlett Foote	Director
Charles Dockendorff	Director
Ronald Gelbman	Director
Pedro Granadillo	Director
Mark Kroll, Ph.D.	Director
Ronald Merriman	Director

## SEC Filings

### Year Filter

All Years

Filing Date	Form	Description
08/15/17	4	Statement of changes in beneficial ownership of securities
08/07/17	3	Initial filing by director officer or owner of more than ten percent.
08/07/17	10-Q	Quarterly report which provides a continuing view of a company's financial position
08/07/17	8-K	Report of unscheduled material events or corporate event

## Ownership Summary

Shareholders				
	Holdings	Value (\$MM)	% O/S	Shares
Institution	295	2,241.95	108.0	56,796,676
Mutual Fund	336	1,284.34	61.1	32,128,469
Insider *	16	18.79	0.9	474,094

\*Insider values reflect direct beneficial ownership.

Top Holders				
	Shares Held	% O/S	Share Change	Filing Date
BlackRock Institutional Trust Company, N.A.	5,863,728	11.2	13,216	06/30/17
The Vanguard Group, Inc.	4,743,044	9.0	48,719	06/30/17
Wellington Management Company, LLP	4,302,355	8.2	110,005	06/30/17
T. Rowe Price Associates, Inc.	3,229,686	6.1	-241,205	06/30/17
Wells Capital Management Inc.	2,263,958	4.3	-59,706	06/30/17
Fuller & Thaler Asset Management Inc.	2,219,997	4.2	10,547	06/30/17
Victory Capital Management Inc.	2,033,514	3.9	-360,621	06/30/17
Neuberger Berman, LLC	1,863,661	3.5	-144,623	06/30/17
HealthCor Management, L.P.	1,854,872	3.5	254,872	06/30/17
Dimensional Fund Advisors, L.P.	1,739,734	3.3	40,381	06/30/17

Powered By **EDGAR** Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed